Compugen (CGEN) Capital Expenditures (2009 - 2010)
Compugen's (CGEN) quarterly Capital Expenditures came in at $88000.0 in Q4 2010, up 23.94% year-on-year from $71000.0 in Q4 2009, and up 344.44% quarter-over-quarter from -$36000.0 in Q3 2010.
Compugen (CGEN) Capital Expenditures (2009 - 2010) Analysis & Trends
Compugen has disclosed Capital Expenditures across 2 years of filings, most recently posting $88000.0 for Q4 2010.
- Capital Expenditures for Q4 2010 came in at $88000.0, up 23.94% year-over-year; the trailing twelve-month figure through Dec 2010 was $112000.0 (changed N/A YoY), and the FY2025 annual result was $306000.0, up 159.32% from the prior year.
- Capital Expenditures came in at $88000.0 for Q4 2010 at Compugen, up from -$36000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $88000.0 in Q4 2010 to a low of -$36000.0 in Q3 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Compugen | 189.59 Mn | 97.83 Mn | 352,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 88,000.00 |
| Dec 31, 2010 | 88,000.00 |
| Sep 30, 2010 | -36,000.00 |
| Sep 30, 2010 | -36,000.00 |
| Dec 31, 2009 | 71,000.00 |
| Dec 31, 2009 | 71,000.00 |
| Sep 30, 2009 | -11,000.00 |
| Sep 30, 2009 | -11,000.00 |